Prophase Labs Inc - PRPH STOCK NEWS

ProPhase Labs (NASDAQ: PRPH), a biotech, genomics and consumer products company, has scheduled a virtual conference call to present its full year 2024 financial results on March 31, 2025, at 11:00 AM EST. The presentation, hosted by Renmark Financial, will include the company's financial performance and a review of current company strategy.

A press release containing detailed financial results will be issued before the virtual conference call. Stakeholders, investors, and other interested parties are invited to register and attend the live event through Renmark Financial's platform. A replay of the presentation will be made available on ProPhase's investor website following the event.

ProPhase Labs (NASDAQ: PRPH), a next-generation biotech, genomics, and consumer products company, has announced its participation in the upcoming Q1 Investor Summit Virtual on March 11, 2025. CEO Ted Karkus will deliver a presentation at 1:30 P.M. ET.

The Investor Summit is an exclusive event focused on small and microcap stocks, specifically targeting undervalued MicroCap companies with catalysts. The event provides investors an opportunity to interact with management teams, learn from industry experts, and network with peers.

Interested investors can register for free at the Investor Summit Group website to access the presentation, which will be available at the provided webcast link.

ProPhase Labs (NASDAQ: PRPH) is exploring strategic opportunities to leverage its direct-to-consumer (DTC) multi-media infrastructure with telehealth physician networks for prescription drugs. The company has been approached with prospects to partner with or potentially acquire telehealth companies that have extensive physician networks nationwide.

Following the hiring of Stu Hollenshead as COO, who has experience at Barstool Sports, Business Insider, and WWE, ProPhase is implementing strategic cost-cutting measures to focus resources on new DTC marketing initiatives. The company has strengthened its balance sheet through the sale of Pharmaloz Manufacturing and enhanced efficiency at Nebula Genomics through streamlined operations and overhead reductions.

ProPhase dispelled rumors of a capital raise, stating no investment banking initiative is underway. Instead, the company is working to secure a revolving line of credit until either Nebula Genomics is sold or the company begins receiving accounts receivable from its litigation initiative, which could potentially net $50 million or more starting mid-year 2025.

The company expressed confidence in maintaining its NASDAQ listing, suggesting multiple pathways for its stock to surpass $1 per share without a reverse split.

ProPhase Labs (NASDAQ: PRPH) is pursuing two major initiatives for immediate cash generation: collection of COVID-19 testing receivables and potential sale of its genomics assets. The company has partnered with Crown Medical Collections to recover over $150 million in uncollected COVID-19 testing receivables from insurance companies. Crown estimates potential net collections exceeding $50 million, which is more than double ProPhase's current market cap, with cash flow expected to begin by June/July 2025.

The company is also exploring strategic alternatives, including the potential sale of Nebula Genomics and DNA Complete. Nebula Genomics possesses a database of over 65,000 whole genome sequenced customers, equivalent to more than 150 million typical ancestry tests. The company will present these initiatives during a Virtual Non-Deal Roadshow on February 25, 2025.

ProPhase Labs (NASDAQ: PRPH) has appointed Stu Hollenshead as Chief Operating Officer, following his previous role as COO and CBO at Barstool Sports. This appointment aims to accelerate the company's consumer-facing strategy in health and wellness products. The company expects significant progress in accounts receivables between Q2-Q3 2025 and is exploring strategic alternatives for Nebula Genomics and DNA Complete.

Former COO Jed Latkin has transitioned to a consulting role focusing on the BE-Smart esophageal cancer test, which targets a $7-14 billion U.S. market. The company is preparing the next batch of samples with The Mayo Clinic to validate the test's effectiveness.

ProPhase will leverage Hollenshead's connection with 10PM Curfew, a platform reaching 70 million women, to scale new product launches including Legendz XL, Legendz Triple Edge, and upcoming Equivir.

ProPhase Labs (NASDAQ: PRPH) has completed the sale of its subsidiaries, Pharmaloz Manufacturing and Pharmaloz Real Estate Holdings, to a Houston-based private equity firm for approximately $23.6 million. This transaction significantly strengthens ProPhase’s balance sheet by eliminating over $20 million in debt and other financial obligations.

The sale includes:

• Receipt of approximately $2 million in cash payments
• Extinguishment of approximately $10 million in debt
• Cancellation of approximately $300,000 in accrued interest
• Paydown of $200,000 on an existing loan
• Assumption of approximately $3 million in current payables
• Buyout of an existing capital lease worth almost $2 million
• Assumption of the $3.3 million mortgage on PMI's facility
• Transfer of over $600,000 in employee annual overhead
• Avoidance of approximately $3 million in planned near-term capital expenditures

This strategic move allows ProPhase to focus on its core businesses, including the BE-Smart Esophageal Cancer Test, TK Supplements, and DNA Complete, while improving its liquidity and reducing overhead costs.

ProPhase Labs (NASDAQ: PRPH) has announced several strategic initiatives. The company has secured a flexible, low-interest rate debt financing agreement with a global private equity fund, which is expected to eliminate the need for future equity financing in the near term. The agreement also opens opportunities to distribute ProPhase TK supplements throughout Asia.

The company is in final negotiations with a major lozenge brand for a contract that would fully utilize Pharmaloz's upcoming high-tech production line #2, which is positioned to be one of North America's most advanced lines with enhanced automation and efficiency. The company estimates a 12-month timeline for Line #1.

ProPhase Labs (NASDAQ: PRPH) reported financial results for Q3 2024, showing net revenue of $3.1 million compared to $8.4 million in Q3 2023. The company reported a net loss of $6.6 million, or $(0.35) per share. Key highlights include Pharmaloz Manufacturing projecting $15+ million in revenues and $5+ million in pre-tax earnings over the next 12 months, potential elimination of $6 million in annual overhead expenses in 2025, and strategic initiatives across multiple subsidiaries. The company maintains $3.1 million in cash and cash equivalents as of November 12, 2024. Notable developments include BE-Smart Esophageal Cancer Test partnerships, DNA Complete and DNA Expand launch, and upcoming Equivir clinical study results.

ProPhase Labs announced the closing of its underwritten public offering of 4,795,500 shares of common stock, including 625,500 shares from the underwriter's fully exercised option. Shares were sold at $0.72 per share, generating gross proceeds of approximately $3.45 million. The company plans to use proceeds for working capital, general corporate purposes, capital expenditures, product development, and potential acquisitions. ThinkEquity served as the sole book-running manager for the offering, which was conducted under an effective shelf registration statement.